Publication of national evidence-based guidelines for the management of lymphoma

Impact: Economic impacts, Health impacts, Political impacts


I have participated in three national writing groups to develop practice guidelines for the evidence-based clinical management of lymphoma:the NICE guideline development group for the management of Non-Hodgkin Lymphoma (NICE July 2016 ), and BCSH task force writing committees for guidelines on the management of DLBCL (Chaganti et al, BJH July 2016); and the management of primary CNS lymphoma (fox et, al in press). The publication of these guidelines has influenced and standardised and and Prettyjohns et al, BJH 2018reviewed all the published evidence for this topic, and contributed to the health economic cost effectiveness analysis and development of a new recommendation to offer a new treatment - rituximab - to patients with asymptomatic advanced stage follicular lymphoma. This recommendation has changed practice in the UK (per the NICE guidelines) and with this publication has the potential to change practice internationally. This is at least a 3* output.
Category of impactEconomic impacts, Health impacts, Political impacts